Musculoskeletal
Inflammatory / Fibrotic
Therapeutic Area
15-PGDH INHIBITOR (Oral)
PRECLINICAL
IND ENABLING
PHASE 1
PHASE 2
SarcopeniaPotential label expansion: Sarcopenic obesity
MF-300
Phase 2b in start-up
MF-300 Upcoming Milestones:
-
Ph2 Open-label:
- FPI: Q4 ’27
- 12-week Data: Q2 ’27
- 24-week Data: Q3 ’27
-
Ph2 Double Blind:
- FPI: Q1 ’28
- Top Line Data: Q1 ’28
Osteoporosis*
MF-300
Phase 2 ready
Spinal Muscular Atrophy (SMA)
NCE
Preclinical Efficacy
Irritable Bowel Disease (IBD)
NCE
Preclinical Efficacy
Idiopathic Pulmonary Fibrosis
NCE
Preclinical Efficacy